Literature DB >> 23314731

Epidemiologic features of borderline ovarian tumors in California: a population-based study.

Cyllene R Morris1, Lihua Liu, Anne O Rodriguez, Rosemary D Cress, Kurt Snipes.   

Abstract

PURPOSE: Borderline ovarian tumors (BOT) became no longer reportable in 2001, and few registries still collect information on these still poorly understood tumors. This study's objective was to describe epidemiologic features, trends, and survival of BOTs compared with those of low-grade (LG) and high-grade (HG) epithelial ovarian cancer (EOC) in the large and diverse population of California.
METHODS: Data from the California Cancer Registry were used to examine demographic and tumor characteristics among women diagnosed with BOT (n = 9,786), LG-EOC (n = 3,656), and HG-EOC (n = 40,611) from 1988 to 2010. Annual percent changes in BOT and LG-EOC incidence rates were estimated using Joinpoint regression; 5-year relative survival was calculated for both BOTs and LG-EOCs by age, race/ethnicity, and histology.
RESULTS: Age-adjusted incidence rates of BOT in 2009 were 3.1, 2.3, 2.2, and 1.4 per 100,000 among whites, Latinas, African Americans, and Asian/Pacific Islanders, respectively. Incidence rates for LG-EOC decreased by 2.2 % per year; rates for BOT increased by 7.3 % per year until 1993, remained unchanged until 2006, and seemed to decline thereafter. Compared with LG-EOCs, BOTs were diagnosed in higher frequency among Latinas, at younger age, and were more likely to affect only one ovary. Overall, 5-year relative survival for BOT was 98.9 %; among women diagnosed with stage IV BOT, survival was 77.1 %.
CONCLUSIONS: In this study, differences between BOTs and LG-EOCs were marked but varied substantially by histologic subtype and were far less dramatic than differences between BOTs and HG-EOCs. Findings underscore the importance of understanding these enigmatic tumors.

Entities:  

Mesh:

Year:  2013        PMID: 23314731     DOI: 10.1007/s10552-013-0145-9

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  10 in total

1.  Mucinous borderline ovarian tumors: Analysis of 75 patients from a single center.

Authors:  Duygu Kavak Cömert; Işın Üreyen; Alper Karalok; Tolga Taşçı; Osman Türkmen; Reyhan Öcalan; Taner Turan; Gökhan Tulunay
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-01-12

2.  Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Authors:  Russell Vang; Charlotte G Hannibal; Jette Junge; Kirsten Frederiksen; Susanne K Kjaer; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2017-06       Impact factor: 6.394

3.  A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Kirsten Frederiksen; Anette Kjaerbye-Thygesen; Klaus Kaae Andersen; Ann Tabor; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2014-06-10       Impact factor: 5.482

4.  Feasibility of Single-Port Access (SPA) Laparoscopy for Large Ovarian Tumor Suspected to Be Borderline Ovarian Tumor.

Authors:  Jun-Hyeok Kang; Joseph J Noh; Soo Young Jeong; Jung In Shim; Yoo-Young Lee; Chel Hun Choi; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae; Hyun-Soo Kim; Tae-Joong Kim
Journal:  Front Oncol       Date:  2020-09-16       Impact factor: 6.244

5.  Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.

Authors:  Nicole Urban; Sarah Hawley; Holly Janes; Beth Y Karlan; Christine D Berg; Charles W Drescher; JoAnn E Manson; Melanie R Palomares; Mary B Daly; Jean Wactawski-Wende; Mary J O'Sullivan; Jason Thorpe; Randal D Robinson; Dorothy Lane; Christopher I Li; Garnet L Anderson
Journal:  Gynecol Oncol       Date:  2015-09-03       Impact factor: 5.482

6.  Etiology of Ascites and Pleural Effusion Associated with Ovarian Tumors: Literature Review and Case Reports of Three Ovarian Tumors Presenting with Massive Ascites, but without Peritoneal Dissemination.

Authors:  Ai Miyoshi; Takashi Miyatake; Takeya Hara; Asuka Tanaka; Naoko Komura; Shinnosuke Komiya; Serika Kanao; Masumi Takeda; Mayuko Mimura; Masaaki Nagamatsu; Takeshi Yokoi
Journal:  Case Rep Obstet Gynecol       Date:  2015-12-17

7.  Safety and fertility outcomes after the conservative treatment of endometrioid borderline ovarian tumours.

Authors:  Shuang-Zheng Jia; Jun-Ji Zhang; Zhi-Yong Liang; Jun-Jun Yang; Yang Xiang; Cong-Wei Jia; Jin-Hua Leng
Journal:  BMC Cancer       Date:  2018-11-23       Impact factor: 4.430

8.  Retrospective Analysis of Factors Affecting Recurrence in Borderline Ovarian Tumors.

Authors:  Mariam Anjum Ifthikar; Anupama Rajanbabu; Indu R Nair; Vinita Murali; Anjaly S Nair
Journal:  South Asian J Cancer       Date:  2021-03-19

9.  Nationwide population-based study of prevalence and trend of borderline ovarian tumors in the Republic of Korea.

Authors:  Yung-Taek Ouh; Dongwoo Kang; Hoseob Kim; Jae Kwan Lee; Jin Hwa Hong
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

10.  Detection of early stage ovarian cancer in a large community cohort.

Authors:  Elizabeth J Suh-Burgmann; Mubarika Alavi
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.